Levodopa/carbidopa (ND0612) vs Levodopa (Inbrija)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Levodopa/carbidopa (ND0612) · Onerji
Marketed by NeuroDerm Ltd.
NCT02577523 · Phase 2 · completed
Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.
Reported efficacy
Change in Daily "OFF" Time (Baseline to Day 28): Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5) (unclear)
Result source: NCT02577523
Levodopa (Inbrija)
Marketed by Merz Therapeutics and partners
NCT02240030 · Phase 3 · completed
This randomized, double-blind, placebo-controlled phase 3 trial assigned 351 participants to CVT-301 60 mg, CVT-301 84 mg or placebo. Its clinical primary endpoint, the change in UPDRS motor score from predose to 30 minutes post-dose at week 12 for 84 mg versus placebo, was met: -9.83 versus -5.91, a difference of -3.92 points (95% CI -6.84 to -1.00; p=0.0088), as reported in the peer-reviewed publication.
Reported efficacy
Unified Parkinson's Disease Rating Scale (UPDRS) Part III (30 minutes post-dose at week 12): UPDRS motor score change, predose to 30 min post-dose at week 12: CVT-301 84 mg -9.83 vs placebo -5.91; difference -3.92 (95% CI -6.84 to -1.00), p=0.0088 (LeWitt et al., Lancet Neurol 2019) (met)
Result source: NCT02240030
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Levodopa/carbidopa (ND0612) | Levodopa (Inbrija) |
|---|---|---|
| OFF time, change | -2.1 vs -1.4−0.7 vs placeboNCT01883505 | —Not reported |
| ON time without troublesome dyskinesia, change | —Trial running · NCT04006210 | —Not reported |
| UPDRS Part III, change | —Trial running · NCT04006210 | -9.8 vs -5.9−3.9 vs placeboNCT022400304 other results
|
| MDS-UPDRS Part II, change | —Trial running · NCT04006210 | —Not reported |
OFF time, change
- Levodopa/carbidopa (ND0612)
- -2.1 vs -1.4−0.7 vs placeboNCT01883505
- Levodopa (Inbrija)
- —Not reported
ON time without troublesome dyskinesia, change
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
- Levodopa (Inbrija)
- —Not reported
UPDRS Part III, change
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
- Levodopa (Inbrija)
- -9.8 vs -5.9−3.9 vs placeboNCT02240030
4 other results
- -8.5 vs -6.5 NCT02240030
- -9.0 vs -6.5 NCT02240030
- -5.2 vs -4.2 NCT02240030
- -6.5 vs -4.2 NCT02240030
MDS-UPDRS Part II, change
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
- Levodopa (Inbrija)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Levodopa/carbidopa (ND0612): 3 of 4 rows · Levodopa (Inbrija): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Levodopa/carbidopa (ND0612) | Levodopa (Inbrija) |
|---|---|---|
| Dropout rate | —24-hr Infusiona NCT02577523 · Phase 2 show 4 more results—14-hr Infusion NCT02577523 · Phase 2 0%Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination | 14.9%CVT-301 High Doseb NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 4 more results15%CVT-301 Low Dose NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 28.7%HIgh Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 38.5%Low Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 2.5% NCT02352363 · Phase 3 · monotherapy |
| Discontinued due to AEs | —24-hr Infusiona NCT02577523 · Phase 2 show 4 more results—14-hr Infusion NCT02577523 · Phase 2 —Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination | —CVT-301 High Doseb NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 4 more results—CVT-301 Low Dose NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 9.1%HIgh Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 8.1%Low Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 — NCT02352363 · Phase 3 · monotherapy |
| Serious AEs | 10.5%24-hr Infusiona NCT02577523 · Phase 2 show 4 more results10.5%14-hr Infusion NCT02577523 · Phase 2 5.3%Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence 0%Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence 0%Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination | 1.8%CVT-301 High Doseb NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 4 more results5.3%CVT-301 Low Dose NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 8.2%HIgh Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 14.4%Low Dose NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 15.5% NCT02352363 · Phase 3 · monotherapy |
| Most frequent reported AEs | 24-hr Infusiona infusion site nodule 57.9% infusion site erythema 26.3% infusion site bruising 21.1% NCT02577523 · Phase 2 show 4 more results14-hr Infusion infusion site nodule 36.8% infusion site bruising 15.8% infusion site haemorrhage 15.8% NCT02577523 · Phase 2 fatigue 10.5% (placebo 0%) headache 10.5% (placebo 9.1%) abdominal pain lower 5.3% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence blood creatinine abnormal 12.5% (placebo 0%) dental caries 12.5% (placebo 0%) diarrhoea 12.5% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence back pain 12.5% (placebo 0%) pain in extremity 12.5% (placebo 9.1%) abdominal pain lower 0% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence · combination | b cough 14.9% (placebo 1.8%) upper respiratory tract 6.1% (placebo 2.7%) nausea 5.3% (placebo 2.7%) NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 4 more resultscough 15% (placebo 1.8%) throat irritation 7.1% (placebo 0%) dyskinesia 4.4% (placebo 0%) NCT02240030 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 HIgh Dose cough 14.5% fall 10.7% upper respiratory tract infection 7.5% NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 Low Dose cough 16.3% fall 15.7% upper respiratory tract infection 6.5% NCT02242487 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Levodopa/carbidopa (ND0612)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 1 further endpoint in the CSV export.
Levodopa (Inbrija)
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levodopa/carbidopa (ND0612)'s landscape · Levodopa (Inbrija)'s landscape